Daewoong Pharmaceutical completely eliminates US business risks… Nabota global market penetration spur
Daewoong Pharmaceutical’s “U.S. Appeal Court Urgent Temporary Disposition Citation ‘Nabota’ available for sale
Daewoong Pharmaceutical, operating profit of 17 billion won last year… 62% decrease from the previous year
‘Daewoong Pharmaceutical’s import ban on Nabota’ takes effect in the US… Medytox “Sudden domestic civil and criminal litigation”
